Show simple item record

A new concept in cancer care: The supportive care program

dc.contributor.authorEsper, Pegen_US
dc.contributor.authorHampton, Janeten_US
dc.contributor.authorFinn, Johnen_US
dc.contributor.authorSmith, David C.en_US
dc.contributor.authorRegiani, Sandraen_US
dc.contributor.authorPienta, Kenneth J.en_US
dc.date.accessioned2010-04-13T18:41:41Z
dc.date.available2010-04-13T18:41:41Z
dc.date.issued1999en_US
dc.identifier.citationEsper, Peg; Hampton, Janet; Finn, John; Smith, David; Regiani, Sandra; Pienta, Kenneth (1999). "A new concept in cancer care: The supportive care program." American Journal of Hospice and Palliative Care 16(6): 713-722. <http://hdl.handle.net/2027.42/66626>en_US
dc.identifier.issn1049-9091en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/66626
dc.description.abstractThis article describes the findings of a pilot program designed to enter advanced prostate cancer patients into the hospice benefit while they are still being actively treated, but in situations where treatment is known to be primarily palliative in nature. The supportive care program (SCP) combines the medical model’s goal to prolong life with the goal of hospice to palliate symptoms and improve quality of life (QOL). The concept of a SCP was developed to create a team approach where advanced prostate cancer patients who are starting investigational chemotherapy are concurrently enrolled into a hospice program. The objectives were to identify whether SCP improved QOL and continuity of care while remaining cost-effective. Data were collected on patient quality of life, performance status, use of health care resources, and costs for the 36 enrolled patients. A comparison was made to a matched set of 23 control patients. Our findings indicate that the SCP contributes to continuity of care while being cost-effective.en_US
dc.format.extent3108 bytes
dc.format.extent475217 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.titleA new concept in cancer care: The supportive care programen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelFamily Medicine and Primary Careen_US
dc.subject.hlbsecondlevelNursingen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumOncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumHospice of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumFinancial Operations, University of Michigan Health Systems, Ann Arbor, Michiganen_US
dc.contributor.affiliationumUrologic Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michiganen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/66626/2/10.1177_104990919901600608.pdf
dc.identifier.doi10.1177/104990919901600608en_US
dc.identifier.sourceAmerican Journal of Hospice and Palliative Careen_US
dc.identifier.citedreferenceLeland JY, Schonwetter RS: Advances in hospice care. Clinics in Geriatric Medicine. 1997; 13 (2): 381-399.en_US
dc.identifier.citedreferenceLandis SH, Murray T, Bolden S, Wingo PA: Cancer statistics,1998; 48: 6-29.en_US
dc.identifier.citedreferenceKonety BR, Getzenberg RH: Novel therapies for advanced prostate cancer. Seminars in Urologic Oncology. 1997; 15 (1): 33-42.en_US
dc.identifier.citedreferenceTannock IF, Osoba D, Stockle MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. Journal of Clinical Oncology. 1996; 14 (6): 1756-1764en_US
dc.identifier.citedreferenceEsper PS, Pienta KJ: Supportive care in the patients with hormone refractory prostate cancer. Seminars in Urologic Oncology. 1997; 15 (1): 56-64.en_US
dc.identifier.citedreferenceChristakis NA, Escarce JJ: Survival of medical patients after enrollment in hospice programs. New England Journal of Medicine. 1996; 33 (3): 172-178.en_US
dc.identifier.citedreferenceBloom BS, Amenta MO: Prospective payment and the Medicare hospice benefit. American Journal of Hospice and Palliative Care. 1993; 10 (2): 32-39.en_US
dc.identifier.citedreferenceSUPPORT Principal Investigators: A controlled trial to improve care for seriously ill hospitalized patients. JAMA. 1995; 274 (20): 1591-1598.en_US
dc.identifier.citedreferenceCopp G: Palliative care nursing education—A review of research findings. Journal of Advanced Nursing. 1994; 19 (3): 552-557.en_US
dc.identifier.citedreferenceWeissman DE, Ambuel B, Norton AJ, et al.: A survey of competencies and concerns in end of life care for physician trainees. Journal of Pain and Symptom Management. 1998; 15 (2): 82-90.en_US
dc.identifier.citedreferenceJeffrey D: Education in palliative care: A qualitative evaluation of the present and the needs of general practitioners and community nurses. European Journal of Cancer Care. 1994; 3 (2): 67-74.en_US
dc.identifier.citedreferenceFerrell BR, Virani R, Grant M: HOPE. Home care outreach for palliative care education. Cancer Practice. 1998; 6 (2): 79-85.en_US
dc.identifier.citedreferenceBascom PB: A hospital-based comfort care team: Consultation for seriously ill and dying patients. American Journal of Hospice and Palliative Care. 1997; 14 (2): 57-60.en_US
dc.identifier.citedreferenceLynn J, Wilkinson A, Cohn F, Jones SB: Capitated risk-bearing managed care systems could improve end-of-life care. Journal of the American Geriatrics Society. 1998; 46: 322-330.en_US
dc.identifier.citedreferenceEmanuel EJ: Cost savings at the end of life. JAMA. 1996; 275 (24): 1907-1914.en_US
dc.identifier.citedreferenceLubitz JD, Riley GF: Trend in Medicare payments in the last year of life. New England Journal of Medicine. 1993; 328: 1092-1096.en_US
dc.identifier.citedreferenceUnited States Health Care Financing Administration. Medicare Part A Intermediary Manual. DHHS Publication, Part 3, Section 3656.3. Rockville, MD: HCFA, FY 1996.en_US
dc.identifier.citedreferenceEdelstein EG (ed.): First Database Blue Book. New York: Hearst Corporation, 1995.en_US
dc.identifier.citedreferenceCella DF, Tulsky DS, Gray G, et al.: The Functional Assessment of Cancer Therapy (FACT) Scale: Development and validation of the general measure. Journal of Clinical Oncology. 1993; 11: 570-579.en_US
dc.identifier.citedreferenceEsper P, Mo F, Chodak G, et al.: Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy—Prostate instrument. Urology. 1997; 50 (6): 920-928.en_US
dc.identifier.citedreferenceSmith DC, Esper P, Strawderman M, et al.: A Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. Journal of Clinical Oncology. 1999; 17(6): 1664-1671.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.